Showing results (241-250 of 322) with videos related to

Sort By:
Pageof 33
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 13, 2015
Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell LymphomaHo-Young Yhim, Jin Seok Kim, Yeung-Chul Mun, et al.
Medical Mycology|December 12, 2017
Clinical characteristics and outcomes of patients with chronic disseminated candidiasis who need adjuvant corticosteroid therapyYoung-Rock Jang, Min-Chul Kim, Taeeun Kim, et al.
Cancer Research and Treatment|September 4, 2019
Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II TrialSeok Jin Kim, Dok Hyun Yoon, Jin Seok Kim, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|December 12, 2019
Diagnostic utility of STAT6YE361 expression in classical Hodgkin lymphoma and related entitiesCharles Van Slambrouck, Jooryung Huh, Cheolwon Suh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 29, 2012
First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lungJi-Youn Han, Keunchil Park, Sang-We Kim, et al.
Annals of Hematology|January 13, 2016
Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean multicenter retrospective studyJin Seok Kim, Dok Hyun Yoon, Seonyang Park, et al.
Current Problems in Cancer|August 29, 2021
Multicenter, phase II study of response-adapted lenalidomide-based therapy for transplant-ineligible patients with newly diagnosed multiple myeloma without high-risk featuresKwai Han Yoo, Dok Hyun Yoon, Hye Jin Kang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2009
Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma studySeok Jin Kim, Kihyun Kim, Byung Soo Kim, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 22, 2013
High-dose etoposide plus granulocyte colony-stimulating factor as an effective chemomobilization regimen for autologous stem cell transplantation in patients with non-Hodgkin Lymphoma previously treated with CHOP-based chemotherapy: a study from the Consortium for Improving Survival of LymphomaShin Young Hyun, June-Won Cheong, Soo-Jeong Kim, et al.
Cancer Research and Treatment|April 5, 2022
A New Prognostic Index for Extranodal Natural Killer/T-Cell Lymphoma:Incorporation of Serum β-2 Microglobulin to PINKSora Kang, Hyungwoo Cho, Shin Kim, et al.
Pageof 33